 |
|
|
| |
Long-term Follow-up of Safety and Efficacy of
Sofosbuvir-Based HCV DAAs in Pediatric Patients
|
| |
| |
AAS:LD 2020 virtual Nov 11-16
Reported by Jules Levin
Jessica Wen,1 Suzanne Whitworth,2 Daniel H. Leung,3 Philip Rosenthal,4 Chuan-Hao Lin,5 Wikrom Karnsakul,6 Sanjay Bansal,7 Ronen Arnon,8 Rene
Romero,9 Girish S. Rao,10 Michael R. Narkewicz,11 Jonathan R. Honegger,12 Christopher Jolley,13 Maureen M. Jonas,14 Jiang Shao,15 Diana M. Brainard,15 Kathryn Kersey,15 Anuj Gaggar,15 William F. Balistreri,16 Winita Hardikar,17 Regino P. Gonzalez-Peralta18
1University of Pennsylvania and The Children's Hospital of Philadelphia; 2Cook Children's Health Care System, Fort Worth, TX; 3Texas Children's Hospital, Baylor College of Medicine, Houston, TX; 4University of California San Francisco; 5Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA; 6Johns Hopkins University School of Medicine, Baltimore, MD; 7King's College Hospital, London, UK; 8The Mount Sinai Hospital, New York, NY; 9Emory University School of Medicine and Children's Healthcare of Atlanta Inc., GA; 10Riley Hospital for Children at Indiana University Health, Indianapolis, IN; 11Children's Hospital Colorado, University of Colorado School of Medicine, Aurora; 12Nationwide Children's Hospital, The Ohio State University Wexner Medical Center, Columbus, OH; 13University of Florida Health Shands Hospital, Gainesville; 14Boston Children's Hospital, Boston, MA; 15Gilead Sciences, Inc., Foster City, CA; 16Cincinnati Children's Hospital Medical Center, Cincinnati, OH; 17The Royal Children's Hospital Melbourne, Victoria, Australia; 18AdventHealth for Children, AdventHealth Transplant Institute, Orlando, FL
|
| |
|
|
|
|
|
